When SRX gets full Nasdaq listing in USA there will be shares open to 25 million US investors. Biotechs in USA that have growth rates of 75-100% trade at PE ratios of at least 35-40. AT a P.E of 35xeps of 35 cents this year this is sp of $12.25. A PE of 35x next years eps estimate of $69 cents = $24.15 a share. At present sp of $4.20 this is the most undervalued biotech I have ever seen and gap will be filled shortly with new highs. See my earlier prediction. This is my opinion only and do your own work as I have . I have been in industry over 30 yrs.
SRX Price at posting:
$4.17 Sentiment: ST Buy Disclosure: Held
